OBJECTIVES: To describe factors associated with initiation of depot antipsychotic medications in psychiatric outpatients with schizophrenia and recent medication nonadherence. METHODS: A national sample of psychiatrists reported on adult outpatients with schizophrenia who were nonadherent with oral antipsychotic medications in the last year. RESULTS: In total, 17.6% of psychiatrists initiated depot antipsychotic injections. Initiation was significantly and positively associated with public insurance, prior inpatient admission, proportion of time nonadherent, average or above average intellectual functioning, and living in a mental health residence. Use was inversely associated with using second-generation antipsychotics and other oral psychotropic medications prior to medication nonadherence. Psychiatrists who were male, nonwhite, and more optimistic about managing nonadherence were more likely to initiate depot injections. CONCLUSIONS: Initiation of depot injections is a joint function of patient, physician, treatment, and setting factors. Use of long-acting preparations in this population is uncommon despite clinical recommendations urging their use.
OBJECTIVES: To describe factors associated with initiation of depot antipsychotic medications in psychiatric outpatients with schizophrenia and recent medication nonadherence. METHODS: A national sample of psychiatrists reported on adult outpatients with schizophrenia who were nonadherent with oral antipsychotic medications in the last year. RESULTS: In total, 17.6% of psychiatrists initiated depot antipsychotic injections. Initiation was significantly and positively associated with public insurance, prior inpatient admission, proportion of time nonadherent, average or above average intellectual functioning, and living in a mental health residence. Use was inversely associated with using second-generation antipsychotics and other oral psychotropic medications prior to medication nonadherence. Psychiatrists who were male, nonwhite, and more optimistic about managing nonadherence were more likely to initiate depot injections. CONCLUSIONS: Initiation of depot injections is a joint function of patient, physician, treatment, and setting factors. Use of long-acting preparations in this population is uncommon despite clinical recommendations urging their use.
Authors: D Robinson; M G Woerner; J M Alvir; R Bilder; R Goldman; S Geisler; A Koreen; B Sheitman; M Chakos; D Mayerhoff; J A Lieberman Journal: Arch Gen Psychiatry Date: 1999-03
Authors: Anthony F Lehman; Julie Kreyenbuhl; Robert W Buchanan; Faith B Dickerson; Lisa B Dixon; Richard Goldberg; Lisa D Green-Paden; Wendy N Tenhula; Daniela Boerescu; Cenk Tek; Neil Sandson; Donald M Steinwachs Journal: Schizophr Bull Date: 2004 Impact factor: 9.306
Authors: Lesley M Arnold; Stephen M Strakowski; Michael L Schwiers; Jennifer Amicone; David E Fleck; Kimberly B Corey; Jenni E Farrow Journal: Schizophr Res Date: 2004-02-01 Impact factor: 4.939
Authors: Martha Sajatovic; Jennifer Levin; Luis F Ramirez; David Y Hahn; Curtis Tatsuoka; Christopher S Bialko; Kristin A Cassidy; Edna Fuentes-Casiano; Tiffany D Williams Journal: J Clin Psychiatry Date: 2013-12 Impact factor: 4.384
Authors: Katarina Kelin; Alan Jm Brnabic; Richard Newton; Raúl I Escamilla; Liang-Jen Chuo; Malina Simu; Wenyu Ye; William Montgomery; Jamie Karagianis; Haya Ascher-Svanum Journal: Patient Prefer Adherence Date: 2010-09-07 Impact factor: 2.711
Authors: Taishiro Kishimoto; Sohag Sanghani; Mark J Russ; Akeem N Marsh; Joshua Morris; Suparna Basu; Majnu John; John M Kane Journal: Int Clin Psychopharmacol Date: 2017-05 Impact factor: 1.659
Authors: Haya Ascher-Svanum; Xiaomei Peng; Douglas Faries; William Montgomery; Peter M Haddad Journal: BMC Psychiatry Date: 2009-07-29 Impact factor: 3.630